Role of Pioglitazone on Glycemic Control and its Effect on Lipid Profile in Type 2 Diabetics
A. Sohna Chandra Packiavathy¹, M. Ramalingam² and C. Anchana Devi³¹Department of Biochemistry, PRIST University, Thanjavur - 614 904 (India).
²Center for Research and Development, PRIST University, Thanjavur - 613 103 (India).
³Department of Microbiology, Bharathidasan University, Trichy - 620 024 (India).
Abstract: The effect of pioglitazone on glycemic control in type 2 diabetics was analysed in the present study. The study groups consisted of 220 type 2 diabetic patients (110 males, 110 females) and 220 age and sex matched type 2 diabetic subjects treated with pioglitazone (110 males, 110 females). The levels of blood glucose, urea, creatinine, HbA1c were found to be significantly decreased by pioglitazone treatment. Lipid status was also found to be normalised by pioglitazone therapy in type 2 diabetics. Hence pioglitazone can be used more often in patients with type 2 diabetes, because they offer excellent glycemic control as well as decrease in insulin resistance and reductions in cardiac risk factors associated with the insulin resistance.
Keywords: Type 2 diabetes mellitus; pioglitazone; glycemic control Back to TOC